


LDN-211904 oxalate

Cat. No.:	HY-107460
CAS No.:	1198408-78-4
Molecular Formula:	C ₂₁ H ₂₁ ClN ₄ O ₅
Molecular Weight:	444.87
Target:	Ephrin Receptor
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 20 mg/mL (44.96 mM; Need ultrasonic and warming)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.2478 mL	11.2392 mL	22.4785 mL
	5 mM		0.4496 mL	2.2478 mL	4.4957 mL
	10 mM		0.2248 mL	1.1239 mL	2.2478 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

LDN-211904 oxalate (compound 32) is a potent and selective EphB3 inhibitor with an IC₅₀ of 0.079 μM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with cetuximab could be effective in inhibiting STAT3-activated CSC stemness and cetuximab resistance in CRC^{[1][2]}.

IC₅₀ & Target

IC₅₀: 0.079 μM (EphB3)^[1]

REFERENCES

- [1]. Qiao L, et al. Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6122-6.
- [2]. Park SH, et al. Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer. Theranostics. 2019 Apr 12;9(8):2235-2251.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA